Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LHCGR | P22888 | 16/20 | 0.64 |
| ▸ | FSHR | P23945 | 5/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30673522 | 1.00 | LHCGR (0.64) | LHCGRFSHRTSHRBRAF | |
| SCHEMBL5028842 | 0.94 | LHCGR (0.67) | LHCGRFSHRTSHR | |
| SCHEMBL30673524 | 0.94 | LHCGR (0.67) | LHCGRFSHRTSHR | |
| SCHEMBL5028832 | 0.94 | LHCGR (0.67) | LHCGRFSHRTSHR | |
| SCHEMBL30673520 | 0.94 | LHCGR (0.67) | LHCGRFSHRTSHR | |
| SCHEMBL30673521 | 0.93 | LHCGR (0.66) | LHCGRFSHRTSHR | |
| SCHEMBL5025963 | 0.93 | LHCGR (0.66) | LHCGRFSHRTSHR | |
| SCHEMBL5026884 | 0.92 | LHCGR (0.64) | LHCGRFSHRTSHR | |
| SCHEMBL5025965 | 0.92 | LHCGR (0.64) | LHCGRFSHRTSHR | |
| SCHEMBL30673525 | 0.92 | LHCGR (0.64) | LHCGRFSHRTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325555-A1 | Method of Treating Obesity with a Luteinizing Hormone Receptor Agonist | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-10-23 | — | — | US | claimed |
| WO-2023239854-A2 | METHOD OF TREATING OBESITY WITH A LUTEINIZING HORMONE RECEPTOR AGONIST | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-12-14 | — | — | WO | claimed |
| US-7317006-B2 | Thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity | N.V. ORGANON (NL) | 2008-01-08 | — | — | US | claimed |
| EP-1427733-B1 | THIENO[2,3-D]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY | ORGANON NV (NL) | 2006-11-15 | — | — | EP | claimed |
| US-20040180873-A1 | Thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | MERCK SHARP & DOHME B.V. (NL) | 2004-09-16 | — | — | US | claimed |
| US-20250325555-A1 | Method of Treating Obesity with a Luteinizing Hormone Receptor Agonist | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2023239854-A2 | METHOD OF TREATING OBESITY WITH A LUTEINIZING HORMONE RECEPTOR AGONIST | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20080025969-A1 | Treatment of Neurodegenerative Diseases by the Use of Gpr49 | CELL ZOME AG (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080025969-A1 | Treatment of Neurodegenerative Diseases by the Use of Gpr49 | CELL ZOME AG (DE) | 2008-01-31 | — | — | US | disclosed |
| US-7317006-B2 | Thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity | N.V. ORGANON (NL) | 2008-01-08 | — | — | US | disclosed |
| EP-1427733-B1 | THIENO[2,3-D]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY | ORGANON NV (NL) | 2006-11-15 | — | — | EP | disclosed |
| US-20040180873-A1 | Thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | MERCK SHARP & DOHME B.V. (NL) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080025969-A1 | Treatment of Neurodegenerative Diseases by the Use of Gpr49 | GPR65, BACE1, BACE2 | LHCGR 930/4885FSHR 1001/4885TSHR 3654/4885 |
| US-20040180873-A1 | Thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | FSHR, GNRHR, LHCGR | LHCGR 3/4885FSHR 1/4885TSHR 14/4885 |
| US-20250325555-A1 | Method of Treating Obesity with a Luteinizing Hormone Receptor Agonist | GNRHR, LHCGR, FSHR | LHCGR 2/4885FSHR 3/4885TSHR 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.